Top in rheumatology: COVID-19 biomarker, vaccination in children with rheumatic diseases
Click Here to Manage Email Alerts
Researchers found that plasma osteopontin levels were higher in children hospitalized with moderate to severe COVID-19 and MIS-C, suggesting this could be a “reliable biomarker” for disease severity.
A review of the data was the top story in rheumatology last week.
Another top story was about rising COVID-19 rates among children during the back-to-school season and what providers need to know about vaccination in young children with rheumatic diseases.
Read these and more top stories in rheumatology below:
Plasma osteopontin may offer 'reliable biomarker' to predict COVID-19, MIS-C severity
Plasma osteopontin levels are significantly higher in children hospitalized with moderate to severe COVID-19 and MIS-C than in those with mild or asymptomatic cases, suggesting a potential biomarker for disease severity, researchers said. Read more.
COVID-19 vaccines for young children with rheumatic diseases: What providers need to know
The fight against COVID-19 has shifted drastically since the beginning of 2021. The front lines are no longer nursing homes or retirement communities, but school cafeterias and daycare centers. Read more.
Antibiotics exposure in early life linked to juvenile idiopathic arthritis
Exposure to antibiotics in early life is associated with the later onset of juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology. Read more.
Enthesitis-related arthritis, family history, etanercept use tied to IBD risk in JIA
Enthesitis-related arthritis and a family history of autoimmune disease are key risk factors for inflammatory bowel disease in juvenile idiopathic arthritis, according to data published in Rheumatology. Read more.
Elderly patients with SLE, breast cancer at increased risk for mortality
Systemic lupus erythematosus is a risk factor for increased mortality in elderly patients with early breast cancer, according to data published in Arthritis Care & Research. Read more.